阿霉素
蜂毒肽
化学
癌症研究
间质细胞
细胞外基质
免疫系统
渗透(HVAC)
药物输送
细胞毒性T细胞
基质金属蛋白酶
细胞毒性
细胞浸润
肿瘤微环境
化疗
转移
纤维肉瘤
细胞外
全身给药
纳米载体
免疫疗法
基质
癌细胞
炎症
免疫原性细胞死亡
内化
外渗
药理学
药品
作者
Sihan Chen,Yidi Liu,Yang Liu,Renjiang Kong,Yuzhi Qiu,Xi Yu,Ruohong Ju,Xiangliang Yang,Yan Zhang,Yanhong Zhu
出处
期刊:
[American Chemical Society]
日期:2026-10-16
摘要
Abstract The extracellular matrix (ECM) secreted by cancer-associated fibroblasts (CAFs) impedes deep intratumoral infiltration of chemotherapeutic agents and immune cells, resulting in insufficient intratumoral drug accumulation and compromised antitumor efficacy. In this study, we engineered genetically bacterial minicell as a tumor microenvironment-responsive delivery platform to remodel CAFs and facilitate the deep intratumoral penetration of chemotherapeutics. Specifically, the carrier system was designed by encapsulating doxorubicin (DOX) within minicells functionalized with a matrix metalloproteinase 2 (MMP2)-cleavable melittin precursor fusion peptide, designated DOX@MCm. Upon exposure to elevated MMP2 levels in tumor tissue, active melittin is locally released, promoting DOX release while simultaneously enhancing its deep-tissue penetration by inhibiting CAF activation. In both standard and stroma-rich subcutaneous 4T1 tumor models, systemic DOX@MCm treatment significantly restrained primary tumor progression, ameliorated intratumoral fibrosis, elevated intratumoral cytotoxic CD8+ T cell populations, and exhibited minimal systemic toxicity, with no detectable organ injury or body weight loss. Furthermore, DOX@MCm markedly suppressed lung metastasis in stroma-rich subcutaneous 4T1 tumor models. Collectively, this MMP2-activatable melittin-engineered minicell delivery system achieves enhanced deep intratumoral penetration, stromal reprogramming, protease-triggered drug liberation and profoundly augmented antitumor immunity. The DOX@MCm establishes a biocompatible nanoplatform designed for synergistic therapy for stroma-rich solid tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI